Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Conditional knockout of protein O-mannosyltransferase 2 reveals tissue-specific roles of O-mannosyl glycosylation in brain development.

The Journal of comparative neurology | 2011

The meninges produce essential signaling molecules and major protein components of the pial basement membrane during normal brain development. Disruptions in the pial basement membrane underlie neural ectopia seen in those congenital muscular dystrophies (CMDs) caused by mutations in genes involved in O-mannosyl glycosylation. In mammals, biosynthesis of O-mannosyl glycans is initiated by a complex of mutually indispensable protein O-mannosyltransferases 1 and 2 (POMT1 and 2). To study the roles of O-mannosylation in brain development we generated a conditional allele of POMT2. POMT2 nulllizygosity resulted in embryonic lethality because of a defective Reichert's membrane. Brain-specific deletion of POMT2 resulted in hypoglycosylation of α-dystroglycan (DG) and abolished laminin binding activity. The effect of POMT2 deletion on brain development was dependent on timing, as earlier deletion resulted in more severe phenotypes. Multiple brain malformations including overmigration of neocortical neurons and migration failure of granule cells in the cerebellum were observed. Immunofluorescence staining and transmission electron microscopy revealed that these migration defects were closely associated with disruptions in the pial basement membrane. Interestingly, POMT2 deletion in the meninges (and blood vessels) did not disrupt the development of the neocortex. Thus, normal brain development requires protein O-mannosylation activity in neural tissue but not the meninges. These results suggest that gene therapy should be directed to the neural tissue instead of the meninges.

Pubmed ID: 21452199 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-CUX1, (N-terminal) antibody produced in rabbit (antibody)

RRID:AB_10669024

This polyclonal targets CUX1 (N-terminal) antibody produced in rabbit

View all literature mentions

Ctip2 antibody (antibody)

RRID:AB_2049548

This polyclonal targets Ctip2 antibody

View all literature mentions

Beta DG (antibody)

RRID:AB_2314002

This unknown targets

View all literature mentions

CR-50 (antibody)

RRID:AB_2314225

This unknown targets

View all literature mentions

Anti-GABAA Receptor (alpha6 subunit) antibody produced in rabbit (antibody)

RRID:AB_262010

This polyclonal targets GABAA Receptor (alpha6 subunit) antibody produced in rabbit

View all literature mentions

Anti-Laminin antibody produced in rabbit (antibody)

RRID:AB_477163

This polyclonal targets Laminin antibody produced in rabbit

View all literature mentions

Mouse Anti-Rat radial glial cell marker Antibody, Unconjugated (antibody)

RRID:AB_531887

This unknown targets Mouse Rat radial glial cell marker

View all literature mentions

Reticular Fibroblasts and Reticular Fibres antibody [ER-TR7] (antibody)

RRID:AB_881651

This monoclonal targets Reticular Fibroblasts and Reticular Fibres antibody [ER-TR7]

View all literature mentions